How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Tardive Dyskinesia TD Treatment Market
- By Treatment Type: VMAT2 Inhibitors, Anticholinergic Agents, Benzodiazepines, Botulinum Toxin, Other Pharmacological Treatments
- By Drug Class: Deutetrabenazine, Valbenazine, Tetrabenazine, Off-label Medications
- By Patient Demographics: Adult Patients, Geriatric Patients, Pediatric Patients
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
- By End User: Neurologists, Psychiatrists, General Practitioners, Movement Disorder Specialists
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - VMAT2 Inhibitors leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 11 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 11 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Tardive Dyskinesia TD Treatment Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 11 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Drug Class 4
Patient Demographics 3
Distribution Channel 4
End User 4
Companies profiled
Teva Pharmaceutical Industries Ltd.
Neurocrine Biosciences Inc.
Sunovion Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.
H. Lundbeck A/S
Mitsubishi Tanabe Pharma Corporation
Otsuka Pharmaceutical Co. Ltd.
Lundbeck
Mylan N.V.
Valeant Pharmaceuticals International
Inc.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
11 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Neurocrine Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sunovion Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Acadia Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →H. Lundbeck A/S
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Otsuka Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Lundbeck
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Mylan N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Valeant Pharmaceuticals International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,318M by 2033 · 3.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- VMAT2 Inhibitors45.3
- Anticholinergic Agents10.9
- Benzodiazepines11.4
- Botulinum Toxin9.9
- Other Pharmacological Treatments22.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$820.8M → $1,177M · 4.6%
Europe$572.1M → $829.2M · 4.7%
Asia Pacific$522.4M → $723.9M · 4.2%
Latin America$323.4M → $485.4M · 5.2%
Middle East and Africa$248.7M → $366.4M · 5.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.622026
3.632027
3.642028
3.662029
3.672030
3.682031
3.702032
3.702033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Teva Pharmaceutical Industries Ltd.11.8
- Neurocrine Biosciences Inc.17.1
- Sunovion Pharmaceuticals Inc.7.4
- Acadia Pharmaceuticals Inc.5.6
- H. Lundbeck A/S13.2
- Mitsubishi Tanabe Pharma Corporation16.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type25.7%
Drug Class23.3%
Patient Demographics17.0%
Distribution Channel23.8%
End User10.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.9
- Europe23.2
- Asia Pacific20.2
- Latin America13.6
- Middle East and Africa10.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. | 79 | 80 | 88 | 79 | 86 | 87 | 83 |
| Neurocrine Biosciences Inc. | 81 | 70 | 80 | 84 | 84 | 73 | 79 |
| Sunovion Pharmaceuticals Inc. | 87 | 81 | 82 | 86 | 70 | 75 | 80 |
| Acadia Pharmaceuticals Inc. | 63 | 77 | 74 | 58 | 79 | 77 | 71 |
| H. Lundbeck A/S | 67 | 71 | 54 | 62 | 71 | 61 | 64 |
| Mitsubishi Tanabe Pharma Corporation | 52 | 48 | 48 | 59 | 53 | 55 | 53 |
| Otsuka Pharmaceutical Co. Ltd. | 63 | 47 | 42 | 61 | 48 | 66 | 55 |
| Lundbeck | 43 | 58 | 59 | 54 | 50 | 39 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Teva Pharmaceutical Industries Ltd.
- Neurocrine Biosciences Inc.
- Sunovion Pharmaceuticals Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Neurocrine Biosciences Inc. | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Sunovion Pharmaceuticals Inc. | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Acadia Pharmaceuticals Inc. | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| H. Lundbeck A/S | − | ◐ | − | − | ◐ | − |
| Mitsubishi Tanabe Pharma Corporation | − | ◐ | − | − | ◐ | − |
| Otsuka Pharmaceutical Co. Ltd. | ◐ | − | − | − | − | ◐ |
| Lundbeck | − | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Teva Pharmaceutical Industries Ltd.83
2Sunovion Pharmaceuticals Inc.80
3Neurocrine Biosciences Inc.79
4Acadia Pharmaceuticals Inc.71
5H. Lundbeck A/S64
6Otsuka Pharmaceutical Co. Ltd.55
7Mitsubishi Tanabe Pharma Corporation53
8Lundbeck51
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Teva Pharmaceutical Industries Ltd.Neurocrine Biosciences Inc.Sunovion Pharmaceuticals Inc.
Challenger1
Strong scale, closing on the leaders.
Acadia Pharmaceuticals Inc.
Contender1
Focused players with pockets of strength.
H. Lundbeck A/S
Niche3
Specialists in a single segment or region.
Mitsubishi Tanabe Pharma CorporationOtsuka Pharmaceutical Co. Ltd.Lundbeck
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Tardive Dyskinesia TD Treatment Market — a $277M beachhead inside a $4.99B market.
Beachhead (SOM)$277Mobtainable near-term
Serviceable (SAM)$1.89Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
VMAT2 Inhibitors
Best fit — highest urgency & budget in Treatment Type.
Economic buyer81 fit
Anticholinergic Agents
Strong fit — clear ROI and a fast path to value.
End user65 fit
Benzodiazepines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Demographics
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel29%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Tardive Dyskinesia TD Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified22%
Evaluation15%
Closed-won7%
$14.1KCAC
$59KLTV
4.2:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Tardive Dyskinesia TD Treatment Market is a resilient opportunity — $5.71B by 2033, compounding at 4.7%.
TAM · 2025$3.96Btoday
TAM · 2033$5.71Bforecast
CAGR4.7%2027–2033
Cumulative$43.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.71BTotal addressable market
SAM$2.00BServiceable available market
SOM$393MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
11+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.71BLarge & growingTAM by 2033 at 4.7% CAGR
$2.00BServiceable nowreachable with today’s model
$393MBeachhead winobtainable near-term share
11+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.46BBear3.0% CAGR
$5.71BBase4.7% CAGR
$7.31BBull6.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Tardive Dyskinesia TD Treatment Market — a $5.00B market by 2033. Plan: grow share from 10.6% to 16.4%.
Market size · 2033$5.00Btotal addressable
Market CAGR8.6%2027–2033
Target share16.4%from 10.6% today
Revenue ambition$820Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.6% | 16.4% | Ahead |
| Revenue | $488M | $820M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 35.8% | 40.2% | Ahead |
| Customer retention | 85.4% | 93.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $119M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Tardive Dyskinesia TD Treatment Market conversation — a $7.31B market you can size, segment and defend in minutes.
Market size · 2033$7.31Btotal opportunity
Growth5.9%CAGR to 2033
Addressable buyers995+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 3 mopayback period
$59K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
11+players profiled in this market
Coverage includes
Teva Pharmaceutical Industries Ltd.Neurocrine Biosciences Inc.Sunovion Pharmaceuticals Inc.Acadia Pharmaceuticals Inc.H. Lundbeck A/SMitsubishi Tanabe Pharma CorporationOtsuka Pharmaceutical Co. Ltd.Lundbeck+3 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Tardive Dyskinesia TD Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Tardive Dyskinesia TD Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Antidiabetic Sulphonylureas Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAkabane Vaccines Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportVeterinary Anthrax Vaccines Market
Market size, share, segmentation and regional forecast.
$486M market · 2025 base year
View reportMedical Intravenous Infusion Pump Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportEtoposide Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportEnoxolone Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportRaubasine Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportAgrobacterium tumefaciens Competent Cells Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportMethyl Salicylate Patches Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportClotting Factor Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportDiclofenac Patches Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportDehydrated Culture Media Market
Market size, share, segmentation and regional forecast.
$552M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.